Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature
2016; Elsevier BV; Volume: 128; Issue: 24 Linguagem: Inglês
10.1182/blood-2016-05-715987
ISSN1528-0020
AutoresDavid Kavanagh, Sarah McGlasson, Alexa Jury, J. Raymond Williams, Neil Scolding, Christopher Bellamy, Claudia Günther, Diane Ritchie, Daniel P. Gale, Yashpal S. Kanwar, Rachel Challis, Holly Buist, James Overell, Belinda Weller, Oliver Floßmann, Mark Blunden, Éric P. Meyer, Thomas Krucker, Stephen Evans, Iain L. Campbell, Andrew P. Jackson, Siddharthan Chandran, David Hunt,
Tópico(s)Renal Diseases and Glomerulopathies
ResumoKey Points Type I IFN therapies can cause a dose-dependent TMA. Recombinant type I IFN therapies should be stopped at the earliest opportunity in patients who develop TMA.
Referência(s)